Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism

Journal of Endocrinological Investigation

Volumn 21, Issue 6, 1998, Pages 348-352

  Sahin Y ^a   Bayram, F ^a   Kelestimur F ^a   Muderris I ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Cyproterone acetate; Ethinyl estradiol; Finasteride; Hirsutism

Indexed keywords

CYPROTERONE ACETATE; DIANE; ETHINYLESTRADIOL; FINASTERIDE; PRASTERONE SULFATE; TESTOSTERONE;

ARTICLE; BLOOD CHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIRSUTISM; HORMONE BLOOD LEVEL; HUMAN; SINGLE BLIND PROCEDURE; TESTOSTERONE BLOOD LEVEL;

EID: 0031850631     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350769     Document Type: Article

References (20)

1. Barbieri R.L. Hyperandrogenic disorders. Clin. Obstet. Gynecol. 33: 640, 1990.
2. Rittmaster R.S. Medical treatment of androgen-dependent hirsutism. J. Clin. Endocrinol. Metab. 80: 2559, 1995.
3. Neumann F. Pharmacology and potential use of cyproterone acetate. Horm. Metab. 59: 903, 1977.
4. Schriock E.A., Schriock E.D. Treatment of hirsutism. Clin. Obstet. Gynecol. 34: 852, 1991.
5. Sudduth S.L., Koronkowski M.J. Finasteride: the first 5 alpha-reductase inhibitor. Pharmacotherapy 13: 309, 1993.
6. Rittmaster R S. Finasteride. N. Eng. J. Med. 330: 120, 1994.
7. Fruzetti F., Lorenzo D., Parrini D., Ricci C. Effects of finasteride, a 5α-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J. Clin. Endocrinol. Metab. 79: 831, 1994.
8. Moghetti P., Castello R., Magnani C.M., Tosi F., Negri C., Armanini D., Bellotti G., Muggeo M. Clinical and hormonal effects of the 5α-reductase inhibitor finasteride in idiopathic hirsutism. J. Clin. Endocrinol. Metab. 79: 1115, 1994.
9. Hatch R., Rosenfield R., Kim M.H., Tredway D. Hirsutism: implications, etiology, and management. Am. J. Obstet. Gynecol. 140: 815, 1981.
10. Hammerstein J., Meckies J., Leo-Rossberg J. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J. Steroid Biochem. 6: 827, 1975.
11. Tremblay R.R. Treatment of hirsutism with spironolactone. J. Clin. Endocrinol. Metab. 15: 363, 1986.
12. Müderris I., Bayram F., Şahin Y., Keleştimur F., Tutuş A., Ayata D. The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism. Fertil. Steril. 66: 220, 1996.
13. Belisle S., Love E.J. Clinical efficacy and safety of cyproterone acetate in severe hirsutism: result of a multycentred Canadian study. Fertil. Steril. 46: 1015, 1986.
14. Barth J.H., Cherry C.A., Wojnarowska F., Dawber R.P.R. Cyproterone acetate for severe hirsutism: results of a double-blind dose ranging study. Clin. Endocrinol. (Oxf.) 35: 5, 1991.
15. Serafini P., Ablan F., Lobo R.A. 5α-reductase activity in the genital skin of hirsute women. J. Clin. Endocrinol. Metab. 60: 349, 1985.
16. Wong I.A., Morris R.S., Chang L., Spahn M.-A., Stanczyk F.Z., Lobo R.A. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J. Clin. Endocrinol. Metab. 80: 233, 1995.
17. Ciotta L., Cianci A., Calogero A.E., Palumbo M.A., Marletta E., Sciuto A., Palumbo G. Clinical and endocrine effects of finasteride, 5α-reductase inhibitor, in women with idiopathic hirsutism. Fertil. Steril. 64: 299, 1995.
18. Castello R., Tosi F., Perrone F., Negri C., Muggeo M., Moghetti P. Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year cours of therapy and 1-year follow-up. Fertil. Steril. 66: 734, 1996.
19. Neumann F. Pharmacology and potential use of cyproterone acetate. Horm. Metab. 59: 903, 1977.
20. Girard J., Baumann K.B., Buchler U., Zuppinger K., Haas H.G., Staup J.J., Wyss H.I. Cyproterone acetate and ACTH adrenal function. J. Clin. Endocrinol. Metab. 47: 581, 1978.